MARKET

ATNF

ATNF

180 Life Sciences Corp
NASDAQ
1.900
+0.100
+5.56%
Pre Market: 1.930 +0.03 +1.58% 04:34 04/24 EDT
OPEN
1.770
PREV CLOSE
1.800
HIGH
2.070
LOW
1.770
VOLUME
100
TURNOVER
0
52 WEEK HIGH
27.93
52 WEEK LOW
1.330
MARKET CAP
1.62M
P/E (TTM)
-0.0361
1D
5D
1M
3M
1Y
5Y
12 Health Care Stocks Moving In Tuesday's After-Market Session
180 Life Sciences (NASDAQ:ATNF) shares moved upwards by 7.4% to $2.04 during Tuesday's after-market session. ABVC BioPharma and Medpace Hldgs stock increased by 5.15%. Fresh2 Group shares fell 12.9% during the session.
Benzinga · 1d ago
Weekly Report: what happened at ATNF last week (0415-0419)?
Weekly Report · 2d ago
SINT, ATNF and RETO among mid-day movers
Seeking Alpha · 04/17 16:53
INDO, ONVO and HUSA among pre-market losers
InDO, ONVO and HUSA among pre-market losers. Ryvyl -37% on launch of proposed underwritten public offering. Live Nation Entertainment -9% on reports Justice Dept. May file antitrust lawsuit next month. ArcelorMittal -6%.
Seeking Alpha · 04/16 12:28
Weekly Report: what happened at ATNF last week (0408-0412)?
Weekly Report · 04/15 09:54
Weekly Report: what happened at ATNF last week (0401-0405)?
Weekly Report · 04/08 09:56
Weekly Report: what happened at ATNF last week (0325-0329)?
Weekly Report · 04/01 09:56
GOEV, CHEK and MESO among pre-market losers
On the Move GOEV, CHEK and MESO among pre-market losers. LuxUrban Hotels (LUXH) reports preliminary 2023 results. Direct Digital Holdings (DRCT) -44% after Q4 earnings release. Lux Urban Hotels and Altimmune are among the losers.
Seeking Alpha · 03/27 12:28
More
About ATNF
180 Life Sciences Corp. is a clinical-stage biotechnology company focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation and fibrosis. The Company is primary focused on program to treat several inflammatory disorders using anti-TNF (tumor necrosis factor). The Company has three product development platforms: Anti-TNF platform, SCAs platform and a7nAChR platform. Anti-TNF platform is focused on fibrosis and anti-tumor necrosis factor (anti-TNF). SCAs platform is focused on drugs which are synthetic cannabidiol (CBD) or cannabigerol (CBG) analogues (SCAs). a7nAChR platform is focused on alpha 7 nicotinic acetylcholine receptor (a7nAChR). It is conducting clinical trials only for certain indications under the anti-TNF platform. The Company is undertaking preclinical research and development activities for the SCA platform.

Webull offers 180 Life Sciences Corp stock information, including NASDAQ: ATNF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATNF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ATNF stock methods without spending real money on the virtual paper trading platform.